TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change From Baseline in Mean Number of Nocturnal Voids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Adjusted Probability of Participants Achieving a >33% Reduction From Baseline in Number of Nocturnal Voids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of CD4 T cell response against Aspergillus fumigatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine level of TCD8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine level CD4 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inhibitor development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: accuracy of SPECT/CT in diagnosing lymph node metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of SPECT/CT in diagnosing lymph node metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Recommended Phase 2 Dose (RPIID)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of ST1968
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant Death or Need for Ventricular Shunt by 1 Year of Life
Endpoint domain: Mortality/survival
Primary endpoint: Bayley Scales of Infant Development MDI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cognitive Health
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Score on pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in forearm vascular conductance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: HAV primary patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: F2-isoprostanes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Galderma Décolletage Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Correlated brain activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Change in PANSS Total Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Visual Analog Scale (VAS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase II dose (RP2D) of nilotinib in combination with paclitaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total sensory neuropathy scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Successful Self-administration of Third Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuromodulation of motor behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical aspect of the scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: appearance of nose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pressure between nose and intratracheal tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPUAP classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Ability of IP measurement to distinguish patient subgroups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Average Movement Trajectory Error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer Assessment Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End-Stage Liver Disease score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reappearance of T3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scar Comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Hearing Performance of Speech in Noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant Preference for the Baha 6 Max or Baha 5 SP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean glucose value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Language learning success (percent hits)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: MADRS-S
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants with Clinical Significant Change in Vital Sign, Physical Examination Findings, Clinical Laboratory Results and Electrocardiograms (ECGs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Weight-Normalized Total Body Clearance (CL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of organ function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak FVC (L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Normalization of stool consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Markers of Systemic Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Methylation levels of ALU and LINE-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of objective hot flashes per night
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of nighttime awakenings per night
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insulin sensitivity (%S)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Successful Intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Generation of CD8+ CD28+ memory T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean headache intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mobility Inventory for Agoraphobia (MI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Behavioural Avoidance Test (BAT)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Diary Based Sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Improvement of neurological score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Type II diabetes mellitus control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: COPD control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: muscle elongation of spastic muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of systemic inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Jefferson Scale of Physician Empathy- Medical Student Version (JSPE-MS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants in Each Category of Clinical Global Impression-Improvement (CGI-I) Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Final Effectiveness Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability rates
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Office Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease of skin thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: plasma renin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Medication-related problems
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in turning duration at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in turning angular velocity at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in trunk muscles electromyography during turning at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of drooling severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the Motor Activity Log
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of responders using preventive measures for surgical site infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent Change From Baseline in Tumor Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: favorable outcome on the modified Rankin scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Additional Polyps Detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Severity of Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Antibody Response to HPV Type 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody Response to HPV Type 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Clinically Significant Abnormal Laboratory Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High Frequency spectral power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Prevalence of Overweight and Obesity Using Body Mass Index Percentile for Age and Sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of Acanthosis Nigricans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Brief Fatigue Inventory (BFI)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: MD Anderson Symptom Inventory (MDASI)- Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MD Anderson Symptom Inventory (MDASI)- Summed Severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MD Anderson Symptom Inventory (MDASI)- Sadness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Delay time (Td)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contraction time (Tc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustain time (Ts)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relaxation time (Tr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Plasma Concentration Time Curve from Time Zero to Last Quantifiable Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Plasma Concentration Time Curve from Time Zero to Infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration from 0 to 36 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease activity (Fecal calprotectin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Activity (Crohn's disease)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Quality of Life: scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence rate of COVID-19 on day 14
Endpoint domain: Mortality/survival
Primary endpoint: Safety and adverse events (AEs) incidence rate at day 14
Endpoint domain: Adverse events/effects
Primary endpoint: Number of lapses of attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Vertebral Kyphotic angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response according to the Hamilton Rating Scale for Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Common cold symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Remained on Tocilizumab Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Risk of diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tidal impedance variation regional (TIV-ROI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Global End expiratory lung impedance difference (ΔEELI-g)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Regional End expiratory lung impedance difference (ΔEELI- ROI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Compliance regional (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: postoperative quality of recovery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in clinical tests results over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vital signs over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in electrocardiograms (ECGs) over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Determine the incidence of Treatment Adverse Events (AEs) over time
Endpoint domain: Adverse events/effects
Primary endpoint: Pain intensity level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life score change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Correlation between biological data and clinical phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of clinically diagnosed lung cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: number of lung cancer death
Endpoint domain: Mortality/survival
Primary endpoint: Diabetes Self-management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in ADAS-Cog Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: pterygium recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Sperm Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Best Corrected Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Cho/NAA ratios at baseline in tumor and in regions of tumor recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of using sMRI to define proton therapy high dose target volumes
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hematologic values for anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Evaluation ratings of signs and symptoms of facial skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Disability Assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Differentiation of Th17 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cochlear Microphonic Amplitude during Cochlear Implant Insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cochlear Microphonic Amplitude during post-operative audiological appointments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Oxford Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 60 day hospital mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in WOMAC score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: individual risk of breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: DNA Methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: competency of mitral valve repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concordance (AUC) Between High Tumor GC Risk Score and Positive PSMA-PET Imaging Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in quantitative values from Multi-parametric MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placental perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal cutoff values of placental MRI for placenta mediated adverse outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of placenta-mediated adverse pregnancy outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Source Organ Counts Based on Individualized Organ Volumes of Interest (VOIs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Source Organ Residence Time (Total Number of Disintegrations)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Radiation Absorbed Dose Estimates in Target Organs and Whole Body Based on Standard Medical Internal Radiation Dose (MIRD) Methodology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Fatal or Non-fatal Symptomatic Recurrent Venous Thromboembolism
Endpoint domain: Mortality/survival
Primary endpoint: First Treatment-emergent Major Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Need for Pacemaker post TAVR
Endpoint domain: Adverse events/effects
Primary endpoint: Pathologic complete response (pCR) rates
Endpoint domain: Mortality/survival
Primary endpoint: Depression severity measured by HAMD-17
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline Quality of life assessed by Short Form - 36 Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline lung function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Survival Status from baseline
Endpoint domain: Mortality/survival
Primary endpoint: Maximum tolerated dose of study treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Adverse events/effects
Primary endpoint: iAUC glucose 500
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: iAUC insulin 500
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: iAUC glucose 250
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: iAUC insulin 250
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ratio of malignant to total number of lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Objective Response Rate (ORR) by Blood TMB (bTMB) at 16 Mutations/MB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective Response Rate (ORR) by Blood TMB (bTMB) at 21 Mutations/MB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective Response Rate (ORR) by Tissue TMB at 10 Mutations/MB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Subjective Comfort Preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: % change in total body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With Grade ≥3 AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Immune-mediated Adverse Events (imAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End of Intravenous Treatment (EOIV) Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Pulse Rate at End of Intravenous Treatment (EOIV) Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Patients with Successful LMP-specific T Cell Product Match
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes